Suppr超能文献

低(有利)风险前列腺癌的管理。

Management of low (favourable)-risk prostate cancer.

机构信息

Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287-2101, USA.

出版信息

BJU Int. 2011 Dec;108(11):1684-95. doi: 10.1111/j.1464-410X.2010.10489.x.

Abstract

What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. • The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. • Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. • A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.

摘要

已知内容

对于低危前列腺癌,过度治疗很常见,尤其是在老年男性中。 研究新增内容: 在考虑疾病管理选择时,对低危前列腺癌的自然病史进行了回顾。 • 低危前列腺癌的治疗存在争议,由于缺乏对照试验来指导最佳实践,因此选择取决于个人信念,导致实践模式存在很大差异。 • 今天诊断出患有低危前列腺癌的男性经常接受不会改善整体健康结果的治疗。 • 对于选择低危疾病的最佳管理,应采用共同决策方法,考虑患者年龄、整体健康状况、对癌症的生活方式偏好以及治愈性治疗的潜在副作用。

相似文献

1
Management of low (favourable)-risk prostate cancer.
BJU Int. 2011 Dec;108(11):1684-95. doi: 10.1111/j.1464-410X.2010.10489.x.
2
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):175-83. doi: 10.1093/jncimonographs/lgs036.
3
Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393.
4
An evidence review of active surveillance in men with localized prostate cancer.
Evid Rep Technol Assess (Full Rep). 2011 Dec(204):1-341.
6
Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
BJU Int. 2012 Jul;110(2):180-7. doi: 10.1111/j.1464-410X.2011.10679.x. Epub 2011 Nov 23.
8
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.
9
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.
10
A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.
Eur Urol. 2017 Jun;71(6):866-871. doi: 10.1016/j.eururo.2016.12.026. Epub 2017 Jan 24.

引用本文的文献

1
Unlocking the Potential of Against Prostate Cancer.
Plants (Basel). 2025 Jul 31;14(15):2352. doi: 10.3390/plants14152352.
3
The past and present of prostate cancer and its treatment and diagnostics: A historical review.
SAGE Open Med. 2023 Dec 1;11:20503121231216837. doi: 10.1177/20503121231216837. eCollection 2023.
4
Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol.
Cent European J Urol. 2020;73(2):123-126. doi: 10.5173/ceju.2020.0167. Epub 2020 Jun 25.
5
Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance.
Acta Radiol Open. 2019 Jul 31;8(8):2058460119866352. doi: 10.1177/2058460119866352. eCollection 2019 Aug.
6
Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.
J Natl Cancer Inst. 2020 Mar 1;112(3):247-255. doi: 10.1093/jnci/djz112.
8
Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?
Hepatol Int. 2013 Jun;7(2):413-28. doi: 10.1007/s12072-012-9406-z. Epub 2012 Oct 26.
9
The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?
Int Braz J Urol. 2015 Jan-Feb;41(1):10-4. doi: 10.1590/S1677-5538.IBJU.2015.01.03.
10
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy.
Cancers (Basel). 2014 Sep 29;6(4):1986-2011. doi: 10.3390/cancers6041986.

本文引用的文献

1
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
2
The association between diffusion of the surgical robot and radical prostatectomy rates.
Med Care. 2011 Apr;49(4):333-9. doi: 10.1097/MLR.0b013e318202adb9.
3
Impact of comorbidity on survival among men with localized prostate cancer.
J Clin Oncol. 2011 Apr 1;29(10):1335-41. doi: 10.1200/JCO.2010.31.2330. Epub 2011 Feb 28.
4
US urology clinics overprescribe prostate radiotherapy.
Lancet Oncol. 2011 Feb;12(2):122. doi: 10.1016/s1470-2045(11)70022-5.
5
Clinical practice guidelines to inform evidence-based clinical practice.
World J Urol. 2011 Jun;29(3):303-9. doi: 10.1007/s00345-011-0656-5. Epub 2011 Feb 18.
7
Beyond sequencing: new diagnostic tests turn to pathways.
J Natl Cancer Inst. 2011 Feb 16;103(4):290-2. doi: 10.1093/jnci/djr042. Epub 2011 Feb 8.
8
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Nature. 2011 Feb 10;470(7333):269-73. doi: 10.1038/nature09677. Epub 2011 Feb 2.
9
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验